Alligator Bioscience AB (SE:ATORX)
:ATORX
ATORX Stock Chart & Stats
kr0.34
-kr0.03(-72.12%)
At close: 4:00 PM EST
kr0.34
-kr0.03(-72.12%)
Day’s Range― - ―
52-Week Rangekr0.16 - kr2.02
Previous CloseN/A
Volume998.30M
Average Volume (3M)1.75M
Market Cap
kr90.87M
Enterprise Valuekr4.44M
Total Cash (Recent Filing)kr62.20M
Total Debt (Recent Filing)kr60.41M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
May 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding534,516,970
10 Day Avg. Volume1,169,449
30 Day Avg. Volume1,745,933
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.35
Price to Sales (P/S)18.04
P/FCF Ratio-0.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.75
Revenue Forecast (FY)kr11.90M
Bulls Say, Bears Say
Bulls Say
Focused Immuno-oncology Antibody PlatformA concentrated R&D focus on tumor-directed antibody immunotherapies creates a durable scientific moat: antibody platforms and tumor microenvironment approaches require specialized expertise and long development cycles, raising barriers to entry and enabling high-value partnerships if candidates progress.
Collaboration And Licensing Business ModelA partnering/licensing model suits clinical-stage biotech by enabling non‑recurring but non-dilutive milestone and royalty income; structurally this can de-risk cash needs, align incentives with larger pharma partners, and provide durable upside if clinical programs hit validation points.
Prior Demonstrated Revenue Growth CapabilityHistorical revenue growth indicates organizational ability to commercialize or monetize programs via partnerships or services. This prior scaling suggests the company can expand commercial relationships and revenue when pipeline milestones are met, a durable operational capability despite recent setbacks.
Bears Say
Severe Cash Burn And Weak Cash GenerationVery high recurring cash burn and persistently negative operating/free cash flow force continual external financing. Over months this elevates dilution or debt risk, constrains sustained R&D execution, and makes long-term program advancement contingent on successful raises or partner deals rather than internal cash generation.
Deteriorated Balance Sheet And Rising LeverageMaterial weakening of equity and rising debt materially reduces financial flexibility and increases refinancing and covenant risk. A thin capital buffer undermines negotiating leverage with partners and raises the probability that future funding will be costly or dilutive, impairing long-term strategic options.
Persistent Losses And Sharp 2025 Revenue CollapseSustained operating losses and a near-complete revenue collapse indicate structural execution or commercialization setbacks. Over the medium term, this erodes runway, reduces partner confidence, and heightens the need for material program milestones to restore commercial traction and stabilize the business model.
Alligator Bioscience AB News
ATORX FAQ
What was Alligator Bioscience AB’s price range in the past 12 months?
Alligator Bioscience AB lowest stock price was kr0.16 and its highest was kr2.02 in the past 12 months.
What is Alligator Bioscience AB’s market cap?
Alligator Bioscience AB’s market cap is kr90.87M.
When is Alligator Bioscience AB’s upcoming earnings report date?
Alligator Bioscience AB’s upcoming earnings report date is May 05, 2026 which is in 27 days.
How were Alligator Bioscience AB’s earnings last quarter?
Alligator Bioscience AB released its earnings results on Feb 12, 2026. The company reported -kr0.663 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.663.
Is Alligator Bioscience AB overvalued?
According to Wall Street analysts Alligator Bioscience AB’s price is currently Overvalued.
Does Alligator Bioscience AB pay dividends?
Alligator Bioscience AB does not currently pay dividends.
What is Alligator Bioscience AB’s EPS estimate?
Alligator Bioscience AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alligator Bioscience AB have?
Alligator Bioscience AB has 534,516,970 shares outstanding.
What happened to Alligator Bioscience AB’s price movement after its last earnings report?
Alligator Bioscience AB reported an EPS of -kr0.663 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.523%.
Which hedge fund is a major shareholder of Alligator Bioscience AB?
Currently, no hedge funds are holding shares in SE:ATORX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alligator Bioscience AB
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in Sweden. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. The company develops Mitazalimab, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of cancer. The company also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527; and a research collaboration with MacroGenics, Inc. to develop a novel immunotherapy. The company also has a joint research agreement with BioArctic AB (publ) to employ proprietary antibody generation technologies for developing new product candidates; and a research collaboration and license agreement with the Orion Corporation to discover and develop new bispecific antibody cancer therapeutics. Alligator Bioscience AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Technical Analysis
Alzinova AB
―
Nanologica AB
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
NextCell Pharma AB
―